Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Application Number 09/990.611 Substitute for form 1449/PTO November 21, 2001 Filing Date INFORMATION DISCLOSURE First Named Inventor Lorraine Faxon Meisner STATEMENT BY APPLICANT (Use as many sheets as necessary) Art Unit Examiner Name Frank I. Choi Sheet Of 6 Attorney Docket Number 36091-701.302

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	1.	2001/0041193 A1	11-15-2001	Meisner			
	2.	2002/0037314 A1	03-28-2002	Meisner			
	3.	2002/0164386 A1	11-07-2002	Meisner			
	4.	2005/0003023 A1	01-06-2005	Meisner			
	5.	2006/0165819 A1	07-27-2006	Meisner			
	6.	2008/0125395 A1	05-29-2008	Meisner			
	7.	2,400,171	05-14-1946	Ruskin et al.			
	8.	2,442,461	06-01-1948	Karrer			
	9.	3,857,970	12-31-1974	Tsumura, et al.			
	10.	3,886,265	05-27-1975	Evers et al.			
	11.	4,229,430	10-21-1980	Fahim et al.			
	12.	4,294,852	10-13-1981	Wildnauer et al.			
	13.	4,367,157	01-04-1983	Sherman			
	14.	4,515,771	05-07-1985	Fine			
	15.	4,590,067	05-20-1986	Meisner			
	16.	4,647,453	03-03-1987	Meisner			
	17.	4,711,780	12-08-1987	Fahim			
	18.	4,722,936	02-02-1988	Jacob			
	19.	4,772,591	09-20-1988	Meisner			
	20.	4,818,521	04-04-1989	Tamabuchi			
	21.	5,700,451	12-23-1997	Yue, et al.			
	22.	5,703,122	12-30-1997	Duffy			
	23.	5,736,567	04-07-1998	Cantin et al.			

Signature		Considered		
			itation if not in conformance and not considered	
			es of USPTO Patent Documents at www.uspto.go	
			the indication of the year of the mire of the Even	

proceds the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document uniform. WIPO Standard ST 16 if possible. "Applicant is to place a check mark here if English language Translation is attached. This collection of afformation is useful by \$9 CFR, 107 and 108. The information is required to obtain or main a beauth by the politic which is to fit and by the USFTO to process in application. Confidentially in a general by \$1 Str. \$1 C.2 and \$7 CFR, 114 This collection is estimated to the 2 botto to complete, including agreement per \$1 Str. \$1 C.2 and \$7 CFR, 144 This collection is estimated to the 2 botto to complete in applications from the Str. \$1 C.2 and \$7 CFR, 107 and the string of the complete application from the Str. \$1 C.2 and \$1 CFR, 107 CFR

Examiner

Date

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Application Number 09/990.611 Substitute for form 1449/PTO November 21, 2001 Filing Date INFORMATION DISCLOSURE First Named Inventor Lorraine Faxon Meisner STATEMENT BY APPLICANT (Use as many sheets as necessary) Art Unit Examiner Name Frank I. Choi Sheet 2 Of 6 Attorney Docket Number 36091-701.302

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	24.	5,750,123	05-12-1998	Znaiden et al.			
	25.	5,972,993	10-26-1999	Ptchelintsev			
	26.	6,440,465	08-27-2002	Meisner			

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ – Number ⁴ – Kmd Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
	27.	EP 0273202	06-21-1995	Van Scott			
	28.	EP 0771557	08-18-1999	L'Oreal			
	29.	JP 61078715 (English language abstract)	04-22-1986	Shiseido Co. Ltd.		AB	
	30.	WO 98/23152	06-04-1998	Perricone			
	31.	WO 00/56327	09-28-2000	Bioderm, Inc.			
	32.	WO 01/83031	11-08-2001	Bioderm, Inc.			

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
	33.	BANDELIN & TUSCHHOFF, "The Stability of Ascorbic Acid in Various Liquid Media", J. Am. Pharmacol. Assoc. 44(4):241-244 (1955)				
	34.	BAUERNFEIND, "Ascorbic Acid Technology" in ASCORBIC ACID: CHEMISTRY, METABOLISM, AND USES, 417-29 (Seib & Tolbert, eds., American Chemical Society 1982)				
	35.	BEKESI et al., "Inhibitory Effect of D-Glucosamine and Other Sugar Analogs on the Viability and Transplantability of Ascites Tumor Cells", Cancer Research 29:353-359 (1969)				

Signature		Considered
*EXAMINER:	Initial if reference considered, whether or not citation is in conformance with MPEP 609	

of this form with next communication to applicant. Applicant's magac citation designation number (opticated). "See Kinds Codes of USFO Detert Documents at www supro, opc on MPEP 100 (14 "Either Offices that issued the document, by the resolvent code (WFO Standard ST.)." For Japanese puter of contents, the indication of the year of the rejoin process of the serial number of the patter document. "Kind of document by the appropriate symbols as indicated on the document under WFO Standard ST 16 if possible." Applicant is to place a chock much ber if Eitherfühl Integrage Translation is stateded.

Evaminer

Date

cases miss, sive it degrees surgius; perfaced in Statebook as Statebook and London Lon

Sheet

3 Of

6

PTO/SB/08 (07/05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

36091-701.302

Attorney Docket Number

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published.
	36.	BLACK, "Potential Involvement of Free Radical Reactions in Ultraviolet Light-Mediated Cutaneous Damage", <i>Photochemistry and Photobiology</i> 46:213-221 (1987)
	37.	BORNE & PEDEN "Antiinflammatory Activity of Para-Substituted N-Benzenesulfonyl Derivatives of Amino Acids", <i>J. Med. Chem.</i> 15(12):1325-1326 (1972)
	38.	COOKE & MOXON, "The Detection and Measurement of Vitamin C", in VITAMIN C (ASCORBIC ACID), 167-168, 170-171 (Counsell & Hornig, eds., Applied Science Publishers 1981)
	39.	ENGLARD & SEIFTER, "The Biochemical Functions of Ascorbic Acid", Ann. Rev. Nutri. 6:365-406 (1986)
	40.	GUALANO et al., "Anti-inflammatory Activity of S-Adenosyl-L-Methionine: Interference wi the Eicosanoid System", <i>Pharmacology Res. Commun.</i> 15(7):683-695 (1983)
	41.	HAJRATWALA, "Stability of Ascorbic Acid", S.T.P. Pharma, 1(4):281-286 (1985)
	42.	HALL et al., "Anti-Inflammatory Activity of Diazomethyl Ketone and Chloromethyl Ketone Analogs Prepared from N-Tosyl Amino Acids", J. Pharm. Sci. 69(12):1451-1452 (1980)
	43.	HORNIG & MOSER. "The Safety of High Vitamin C Intakes in Man", in VITAMIN C (ASCORBIC ACID) 225-226 (Counsell & Hornig, eds., Applied Science Publishers 1981)
	44.	IMAI et al., "The Antiscorbutic Activity of L-Ascorbic Acid Phosphate Given Orally and Percutaneously in Guinea Pigs", <i>Jap. J. Pharmacol.</i> 317-324 (1967)
	45.	JAIN & KHANNA, "Evaluation of Anti-inflammatory and Analgesic Properties of L-Glutamine", Agents and Actions 11(3):243-248 (1981)
	46.	KAHN et al., "Ultraviolet Light Protection by Several New Compounds", Arch Dermatol. 10 510-517 (1974)

Examiner	Date	
Signature	Considered	

^{**}TEXAMINES: Until all reference considered, whether or not classics in conformance with MFF 690. Does for through classics in for in conformance and not seen of the form with not a conformance and responsible and the conformance and the conforma

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known			
Substitute fo	Substitute for form 1449/PTO			Application Number	09/990,611		
INFORMATION DISCLOSURE			LOSURE	Filing Date	November 21, 2001		
STATEM	STATEMENT BY APPLICANT			First Named Inventor	Lorraine Faxon Meisner		
(Use as	many sheets	as ne	cessary)	Art Unit	1616		
				Examiner Name	Frank I. Choi		
Sheet	4	Of	6	Attorney Docket Number 36091-701.302			

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	47.	KAPLAN et al., "A New Stabilized Ascorbic Acid Solution: Percutaneous Absorption and Effect on Relative Collagen Synthsies", J. Cutaneous Aging & Cosmetic Derm. 1(2):115-121 (1988/89)
	48.	KASSEM et al., "Studies on the Stability of Injectable L-Ascorbic Acid Solutions: III. Effect of Metal-complexing Agents", <i>Pharma. Acta Helvetiae</i> 47:89-97 (1972)
	49.	KASSEM et al., "Studies on the Stability of Injectable L-Ascorbic Acid Solutions: I. Effect of pH, Solvent, Light and Container", Pharmaceutica Acta Helvetiae 44:611-623 (1969)
	50.	KOLATA, "Is Tyrosine the Key to Growth Control?" Science 219:377-378 (1983)
51.		KUNERT & TAPPEL, "The Effect of Vitamin C on in vivo Lipid Peroxidation in Guinea Pigs as Measured by Pentane and Ethane Production", <i>Lipids</i> 18(4):271-273 (1983)
	52.	KWAPISZEWSKI et al., "Synthesis of L-Cysteine and S-Methyl-L-Cysteine Derivatives of Immunotropic and Anti-inflammatory Activity", Arch. Immunol. Et Ther. Exp. 27(6):729-731 (1979)
	53.	LASZLO et al., "Effects of Glucose Analogues (2-Deoxy-D-glucose, 2-Deoxy-D-galactose) on Experimental Tumors", Journal of the National Cancer Institute 24(2):267-278 (1960)
	54.	LIEN et al., "Topical Use of Ascorbic Acid in the Management of Pressure Sore", <i>J. Formosan Med. Assoc.</i> , 75:243-250 (1976)
	55.	LITWIN, "Growth of Human Diploid Fibroblasts in Media with Different Amino Acid Composition", J. Cell Science 14:671-680 (1974)
	56.	NOBILE et al., VITAMIN C: THE MYSTERIOUS REDOX-SYSTEM A TRIGGER OF LIFE?, 23-24 (MIP Press Ltd., Boston, MA 1981)
	57.	PINNELL & MURAD, "Vitamin C and Collagen Metabolism," in CUTANEOUS AGING, 275-292 (Kligman & Tukase, eds. Univ. of Tolyo Press 1988)

Examiner		Date		
Signature		Considered		
*EXAMINER: Is	sitial if reference considered, whether or not citation is in conformance with MPEP 600.	Deaw line through a	station if not in conformance and not considered.	Incl

of this form with next commissionate to applicate. *Applicate* susages existed origination number (system). *See Kinds Codes of USFOP Pieter Document as we way upon or NPET* [90] of "Third Codes in the instead the document, by the two-left code (with OSRanded 15T). *See Kinds Codes of USFOP Pieter Document as we way upon or NPET* [90] of "Third Codes in the instead the colorests," by the two-left code (with OSRanded 15T). *See Appliance part of Comment, the indication of the pieter of the right or the Emperor must preced the senial number of the partner document. *Kind of consument by the appropriate symbols as indicated on the document storker WITO Standed 15T [16T] possible. *Applicant is to place a document to the propriate symbols as indicated on the document storker WITO Standed 15T [16T] possible. *Applicant is to place a dock markles or Efficiently Integrate Third Integrate Third Code (with Pieter Integrate Third Pieter Third Piete

This collection of afformation is useful by \$9 CFR, 107 and 108. The information is required to obtain or main a beauth by the politic which is to fit and by the USFTO to process in application. Confidentially in a general by \$1 Str. \$1 C.2 and \$7 CFR, 114 This collection is estimated to the 2 botto to complete, including agreement per \$1 Str. \$1 C.2 and \$7 CFR, 144 This collection is estimated to the 2 botto to complete in applications from the Str. \$1 C.2 and \$7 CFR, 107 and the string of the complete application from the Str. \$1 C.2 and \$1 CFR, 107 CFR If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

				Complete if Known		
Substitute for form 1449/PTO				Application Number	09/990,611	
INFORMATION DISCLOSURE			LOSURE	Filing Date	November 21, 2001	
STATEM	STATEMENT BY APPLICANT (Use as many sheets as necessary)			First Named Inventor	Lorraine Faxon Meisner	
(Use as				Art Unit	1616	
			Examiner Name	Frank I. Choi		
Sheet	5	Of	6	Attorney Docket Number	36091-701.302	

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	58.	SETNIKAR et al., "Antireactive Properties of Glucosamine Sulfate," Arzneimittel Forschung Drug Research 41:157-161 (1991)
	59.	SMART et al., "Inhibition of 12-0-Tetradecanoylphorbol-13-acetate Induction of Ornithine Decarboxylase Activity, DNA Synthesis, and Tumor Promotion in Mouse Skin by Ascorbic Acid and Ascorbyl Palmitate", Cancer Res. 47:6633-6638 (1987)
	60.	TAPADINHAS et al., "Oral Glucosamine Sulphate in the Management of Arthrosis: Report or a Multi-centre Open Investigation in Portugal", Pharmatherapeutica 3(3):157-168 (1982)
	61.	THE MERCK INDEX: AN EXCYCLOPEDIA OF CHEMICALS AND DRUGS, 110-111 (#845-858) (Windholz, et al. eds., Merck and Co., 9th ed. 1976)
	62.	THOMAS et al., "Anti-inflammatory Activity of Esters of Phenylglycine", Communications J. Pharm. Pharmacol. 26:151-152 (1974)
	63.	WEST & TODD, TEXTBOOK OF BIOCHEMISTRY 795 (The MacMillan Company, New York 1951)
	64	Office Action mailed February 29, 2008 in connection with U.S. Patent Application No. 09/997,663, assigned to Bioderm, Inc., under examination by Examiner Choi at the USPTO
	65.	Claims pending on February 29, 2008 in connection with U.S. Patent Application No. 09/997,003, assigned to Biodernt, inc., under examination by Examiner Choi at the USF TO
	66.	Office Action mailed June 13, 2006 in connection with U.S. Patent Application No. 10/014,708, assigned to blodenic fire, now abandoned
	67.	Claims pending on June 13, 2006 in connection with U.S. Patent Application No. 10/614,768, assigned to Biodern, Inc., now abandoned
	68	Office Action mailed November 5, 2007 in connection with U.S. Patent Application No.

Examiner		Date	
Signature		Considered	
*EXAMINER:	Initial if reference considered, whether or not citation is in conformance with MPEP 609	Draw line through	Include

of this form with next communication to applicant. Applicant's unsoper claims of lengths of member (optional). "See Kinds Codes of USPTO Patent Documents at wave upto goor or MPEP's 901 O4. "Enter Office that is used the document, by the two-letter code (WIPO Standard ST. 3)." For Japanese panel recomment, the indication of the year of the reign of the Emperor must proceed the serial number of the patent document. "Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible." Applicant is to place a check mark here if English language Translation is attached

This collection of afformation is useful by \$9 CFR, 107 and 108. The information is required to obtain or main a beauth by the politic which is to fit and by the USFTO to process in application. Confidentially in a general by \$1 Str. \$1 C.2 and \$7 CFR, 114. This collection is estimated to the 2 botto to complete, including agreement politic by \$1 CFR 107 CFR. \$1 C.2 and \$1 CFR 114. This collection is estimated to the 2 botto to complete indight agreement politic by the complete agreement in the most of time agreement politic by the complete agreement in the If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Receipt date: 07/17/2008

PTO/SB/08 (07/05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the	paperwork Red	uction A	ct of 1995, no persons	required to respond to a collection of inf	ormation unless it contains a valid OMB control number.
				Con	nplete if Known
Substitute for form 1449/PTO				Application Number	09/990,611
INFORM	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Filing Date	November 21, 2001
STATEM				First Named Inventor	Lorraine Faxon Meisner
(Use as				Art Unit	1616
				Examiner Name	Frank I. Choi
Sheet	6	Of	6	Attorney Docket Number	36091-701.302

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	69	Claims pending on November 5, 2007 in connection with U.S. Patent Application No.	L		
		11/389,384, assigned to Bioderin, Inc., now abandoned	_		
	70	Office Action mailed November 2, 2007 in connection with U.S. Patent Application No.			
		10/185,388, assigned to Bioderm, Inc., under examination by Examiner Flood at the USPTO	_		
	71	Claims pending on November 2, 2007 in connection with U.S. Patent Application No.	L		
		10/185,388, assigned to Bioderm, Inc., under examination by Examiner Flood at the USPTO	_		

,		
Examiner Signature	/Frank Choi/	Date Considered 04/06/2009

^{**}TXAMDIS: Into Irreference considered, whether or not distain as in conformance with MPTE 607. Does list through extract to a first conformance and no securities of the first with the conformance and no securities of the first with the conformance and no securities of the first with the conformance and no securities of the first of the first Office that issued the document, by the two-lives conformation of the great of the region of the first Office that issued the document, by the two-lives conformation of the great of the region of the first Office that issued the document, by the two-lives conformation of the great of the region of the first Office that issued the document, by the first Office that issued the document of the first Office that issued the document of the first Office that issued the document of the first Office that issued the document on the TVD Standard TV

cases inter, served refrigion suggester, introduction subsection. The collection of information is required by 37 CFR 197 and 198. The information is required by a collection of information is required by 30 CFR 197 and 198. The information is required by a greatered by 30 USC 122 and 37 CFR 114. This collection is estimated to take 2 hours to complete, including gathering, preparing, and advanting the excellent of the collection is estimated to take 2 hours to complete, including gathering, preparing, and advanting the excellent properties of the collection is excellent formation of the collection in the collection is extended to the collection in the collection is excellent formation of the collection in the collection is excellent formation of the collection of the collect